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Antiretroviral therapy (ART) is lifesaving in patients 
with advanced HIV infection, but the magnitude of beneﬁ  t 
in HIV-infected patients receiving tuberculosis (TB) treat-
ment remains uncertain, and population-based data from 
developing countries are limited. We prospectively collect-
ed data about HIV-infected TB patients from February 2003 
through January 2004 in Ubon-ratchathani, Thailand. Dur-
ing 12 months, HIV was diagnosed in 329 (14%) of 2,342 
patients registered for TB treatment. Of patients with known 
outcomes, death during TB treatment occurred in 5 (7%) 
of 71 who received ART and 94 (43%) of 219 who did not. 
Using multivariate analysis, we found a large reduction in 
the odds of death for patients receiving ART before or dur-
ing TB treatment (odds ratio, 0.2; 95% conﬁ  dence interval, 
0.1–0.5), adjusting for CD4 count, smear status, co-trimoxa-
zole use, and treatment facility. ART is associated with a 
substantial reduction in deaths during TB treatment for HIV-
infected TB patients in Thailand.
T
uberculosis (TB) is one of the most common opportu-
nistic infections and causes of death in HIV-infected 
persons (1). In developing countries, many HIV-infected 
persons frequently receive the diagnosis of HIV infection or 
AIDS after ﬁ  rst having TB diagnosed at a health facility (1). 
The proportion of HIV-infected TB patients who die during 
TB treatment is high: an estimated 6%–39% die during TB 
treatment in sub-Saharan Africa (2,3). Deaths occurring in 
the ﬁ  rst few months after TB diagnosis are more likely TB 
related, whereas deaths occurring later are more likely to be 
attributable to other HIV-related illnesses (4–7).
Thailand has experienced a severe TB/HIV syndemic, 
i.e., 2 diseases acting synergistically to cause excess illness 
and death (8). Almost 600,000 persons are currently HIV 
infected, and >90,000 TB cases are estimated to occur an-
nually (2,9). One fourth of persons in whom AIDS was di-
agnosed ﬁ  rst have TB, and an estimated 12% of TB cases 
in Thailand are HIV associated, although the proportion is 
as high as 40% in some provinces (10).
Antitretroviral therapy (ART), which uses highly ac-
tive combinations of drugs, improves survival in HIV-in-
fected persons (11,12). HIV-infected persons in Thailand 
now have widespread access to ART, but physicians often 
do not prescribe it to HIV-infected TB patients because of 
concerns about drug-drug interactions, overlapping tox-
icities, immune reconstitution syndrome, and pill burden. 
Expert groups and the World Health Organization (WHO) 
also recommend that public health programs make treat-
ment of TB the ﬁ  rst priority and ideally begin ART after 
TB treatment is tolerated and CD4+ T-lymphocyte (CD4) 
count is measured (13). Several studies have now docu-
mented that ART reduces the likelihood of death during 
TB treatment of HIV-infected TB patients, but these stud-
ies relied on retrospective data collection, occurred outside 
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routine public health programs, or involved resource-rich 
countries without large TB or HIV epidemics (14–18). In 
this study, we analyzed data from a prospective, popula-
tion-based surveillance system to estimate the beneﬁ  t of 
ART on reducing mortality during TB treatment in HIV-
infected TB patients living in rural Thailand.
Methods
Setting
Ubon-ratchathani is a large, predominantly rural prov-
ince in northeastern Thailand with a population of 1.7 mil-
lion persons. The rate of reported TB cases is 145/100,000 
persons, and HIV prevalence in women attending public 
antenatal clinics was 0.6% (in 2004). Treatment of TB or 
HIV is offered by 25 health facilities, including 20 Ministry 
of Public Health (MOPH) hospitals, 3 private hospitals, 1 
military hospital, and 1 MOPH outpatient TB and HIV re-
ferral clinic. Except for those who are seriously ill, TB and 
HIV patients are managed in outpatient specialty clinics at 
these facilities.
Data Collection
In 2003, the US Centers for Disease Control and Pre-
vention (CDC) began collaborating with the MOPH and 
Ubon-ratchathani Province on a special project to enhance 
surveillance, monitoring, evaluation, and treatment of TB, 
HIV-associated TB, and multidrug-resistant TB (MDR TB) 
in a project known as the Thailand TB Active Surveillance 
Network. For all patients with a diagnosis of TB in any of 
the 25 participating healthcare facilities, public health staff 
recorded standardized epidemiologic data, collected spu-
tum specimens for laboratory testing (including staining 
for acid-fast bacilli [AFB], mycobacterial culture, species 
identiﬁ  cation, and drug-susceptibility testing), and offered 
HIV counseling and testing.
Sputum specimens were collected for AFB staining 
and culture at the beginning of TB treatment. Specimens 
were cultured at an MOPH laboratory in the province on 
Ogawa (February–March 2003) or Lowenstein-Jensen agar 
(April 2003–January 2004) by using standard methods, and 
isolates were sent to the MOPH national reference labora-
tory for drug-susceptibility testing. Public health staff from 
the TB program collected patient data prospectively from 
routine medical and laboratory records, recorded data in a 
modiﬁ  ed version of the standard national TB register, and 
entered data into an electronic database.
Patient Population
All persons registered for TB treatment, regardless of 
their ﬁ  nal diagnosis, were considered TB patients, consis-
tent with WHO guidelines (19). We restricted our analysis 
to TB patients who had laboratory conﬁ  rmation of HIV in-
fection and who were registered for TB treatment from Feb-
ruary 2003 through January 2004. Patient outcomes were 
only recorded through the end of TB treatment, which was 
usually 6 months after treatment initiation; no data about 
outcomes were recorded after the end of TB treatment.
For TB treatment, patients received standardized regi-
mens, consistent with WHO guidelines; new (not previous-
ly treated) patients received isoniazid, rifampin, ethambu-
tol, and pyrazinamide (18). HIV-infected TB patients were 
referred to HIV-related care and treatment, but individual 
physicians used their own clinical judgment about mea-
suring CD4 count, providing opportunistic infection pro-
phylaxis or ART, and managing other clinical conditions. 
When measured, CD4 counts were usually checked within 
the ﬁ  rst month of TB treatment. Thai MOPH guidelines 
recommend that HIV-infected patients with CD4 <200 
cells/mm3 receive co-trimoxazole and stavudine, lamivu-
dine, and nevirapine (known as “GPO-vir”); in patients 
with TB, efavirenz is recommended instead of nevirapine.
Deﬁ  nitions
Standard WHO deﬁ   nitions were used to categorize 
patients according to previous TB treatment history, type 
of TB (sputum smear–positive, pulmonary; sputum smear–
negative, pulmonary; extrapulmonary), and treatment out-
come. Consistent with WHO guidelines, we classiﬁ  ed all 
deaths occurring during TB treatment, whether the cause 
was known or not, as a TB death (18).
We classiﬁ  ed ART use according to whether ART was 
begun before TB treatment, begun during TB treatment, or 
not taken during TB treatment. We classiﬁ  ed co-trimoxa-
zole use as either taken or not taken during TB treatment. 
No data on interruptions of ART or co-trimoxazole treat-
ment were collected; for the purposes of surveillance, any 
patient already taking or started on ART or co-trimoxazole 
was considered to be taking it throughout TB treatment. 
We stratiﬁ  ed CD4 count (cells/mm3) as <50, 50–99, 100–
199, and >200.
Data Analysis
For descriptive analysis, all patients were included. 
For univariate and multivariate analysis of risk factors 
for death, we restricted our analysis to TB patients with 
an outcome of cured, completed, failed, or died; we ex-
cluded patients who defaulted on treatment or transferred 
out, because their ﬁ  nal treatment outcome was not known. 
Patients with an outcome of failure were combined with 
those who were cured or completed treatment, since all 3 
groups were known to have survived the ﬁ  rst 6 months of 
TB treatment. We calculated relative risk (RR) for fac-
tors associated with death in patients with all forms of 
TB and in the subset of patients with pulmonary, sputum 
smear–positive TB.Antiretroviral Therapy and Tuberculosis
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For multivariate analysis, we calculated adjusted odds 
ratios (OR) for factors associated with death by using lo-
gistic regression. Variables were chosen based on >1 of 
the following: statistical signiﬁ  cance (p<0.05) in univariate 
analysis, biologic plausibility, or previously published evi-
dence. Because 41% of patients had data missing for CD4 
count, we performed several analyses to explore the impact 
of missing CD4 count on our ﬁ  nal model estimates, includ-
ing the following: 1) classifying patients with unknown CD4 
as a separate strata in analysis; 2) recoding patients with 
unknown CD4 as having CD4 <50 cells/mm3; 3) recoding 
patients with unknown CD4 as CD4 >200 cells/mm3; and 
4) excluding all patients with unknown CD4 from the anal-
ysis. Because rates of default were high and cases of default 
may actually be deaths, we also recoded cases of default as 
death and repeated all multivariate analyses. In analyses for 
which there were no outcomes in some CD4 strata, we log-
transformed the CD4 count and modeled it as a continuous 
variable (20). The protocol for this project was reviewed by 
the Thailand MOPH and CDC and the study was found to 
be surveillance and public health program implementation 
and not human subjects research requiring oversight by an 
institutional review board.
Results
From February 2003 through January 2004, 2,342 pa-
tients were registered for TB treatment in Ubon-ratchathani 
Province. Of these, 225 (10%) were known to be HIV in-
fected before their TB diagnosis. Of the remaining 2,117 
patients, 1,626 (77%) received HIV pretest counseling, 
680/1,626 (42%) agreed to HIV testing, and 104/680 (15%) 
were found to be HIV infected. In all, 329 (14%) of the 
2,342 total TB patients were either known to be HIV infect-
ed before TB diagnosis (225; 68% of all TB/HIV patients) 
or were identiﬁ  ed as HIV infected after testing through the 
TB program (104; 32% of all TB/HIV patients).
The median age of the 329 HIV-infected TB patients 
was 32 years (range 10 months–68 years), 112 (34%) were 
female, and 307 (93%) had new TB cases (Table 1). TB 
was classiﬁ  ed as sputum smear–positive in 120 (36%), spu-
tum smear–negative in 107 (33%), and extrapulmonary in 
102 (31%). CD4 count was unavailable or not performed in 
134 (41%). Of the 195 patients with CD4 results available, 
the median CD4 count was 53 cells/mm3 (range 1–873); 
93% had CD4 <200 cells/mm3.
Sputum cultures were performed in 145 (64%) of 227 
patients with pulmonary TB, including 93 (78%) of 120 
with sputum smear–positive TB and 52 (49%) of 107 with 
sputum smear–negative TB (Table 2). Of the 93 patients 
whose sputum smears were positive and who had a culture 
performed, 65 (70%) grew Mycobacterium tuberculosis 
(MTB); of these, 4 (6%) isolates were resistant to at least 
isoniazid and rifampin, i.e., MDR TB. Of the 52 sputum 
smear–negative patients with a culture performed, only 3 
(6%) were culture positive, and none exhibited MDR TB.
Before TB treatment, 30 (9%) patients were receiving 
ART; an additional 45 (14%) patients began ART during 
TB treatment; and the remaining 254 (77%) patients did not 
receive ART before or during TB treatment. In 40 of the 45 
patients who began ART during TB treatment and in whom 
a date of starting ART was available, the median time be-
tween TB diagnosis and ART initiation was 93 days (range 
0–170 days). Among all patients receiving ART, 38 (51%) 
received a combination regimen of stavudine, lamivudine, 
and nevirapine; 35 (47%) received efavirenz instead of ne-
virapine; and 2 (2%) were on other regimens. During TB 
treatment, 225 (68%) received co-trimoxazole.
Of all 329 patients, 187 (57%) were cured or complet-
ed TB treatment; 99 (30%) died during TB treatment. In 
Table 1. Characteristics of HIV-infected patients with tuberculosis 
(TB), Ubon-ratchathani, February 2003 through January 2004 
Characteristic
Patients
(N = 329), no. (%) 
Female 112 (34) 
Median age, y (range)  32 (0.8–68) 
Type, location of TB 
   Sputum smear-positive, pulmonary  120 (36) 
   Sputum smear-negative, pulmonary  107 (33) 
   Extrapulmonary  102 (31) 
Category of TB 
   New  307 (93) 
   Treatment after interruption, failure,  
  default, or relapse 
11 (4) 
   Other  11 (3) 
HIV status known before TB diagnosis  225 (68) 
CD4 count (cells/mm
3)
   <50  95 (29) 
   50–99  39 (12) 
   100–199  36 (11) 
>200 25 (8)
   Unknown  134 (41) 
Received co-trimoxazole during TB 
treatment
225 (68) 
Received antiretroviral therapy (ART) 
   Before TB diagnosis  30 (9) 
   During TB treatment  45 (14) 
   Not prescribed ART  254 (77) 
Among patients receiving ART, regimen 
prescribed (n = 75) 
   Stavudine/Lamivudine/Nevirapine  38 (51) 
   Stavudine/Lamivudine/Efavirenz  35 (47) 
   Other  2 (2) 
Treatment outcome 
   Cured  61 (19) 
   Completed  126 (38) 
   Failure  4 (1) 
   Default  31 (9) 
   Transfer  4 (1) 
  Change of diagnosis  4 (1) 
 Died  99  (30) RESEARCH
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the remaining 43 patients, treatment failed (for 4 patients) 
or the patient defaulted (a WHO term deﬁ  ned as missing 
at least 2 continuous months of treatment) (31 patients), 
transferred out (4 patients), or received a ﬁ  nal diagnosis 
other than TB (4 patients). Of the 4 patients with MDR TB, 
3 died and 1 was recorded as having failed treatment with 
ﬁ  nal outcome not recorded.
In univariate analysis restricted to the 290 patients 
with an outcome of cured, completed treatment, failed 
treatment, or died, we analyzed several factors associated 
with death during TB treatment. For all TB patients, hav-
ing an unknown CD4 count was associated with increased 
likelihood of death, and receiving co-trimoxazole or ART 
was associated with reduced mortality (Table 3). For ART, 
5 (7%) of 71 patients who received ART died compared 
with 94 (43%) of 219 patients who did not receive ART 
(RR 0.2; 95% conﬁ  dence interval [CI] 0.1–0.4; absolute 
risk reduction 36; number-needed-to-treat 2.8). For sputum 
smear–positive TB patients, results were similar; addition-
ally, male patients were at higher risk for death than female 
patients (RR 2.3, 95% CI 1.1–4.7).
In multivariate analysis adjusted for CD4 count, smear 
status, hospital providing treatment, and co-trimoxazole 
use, ART remained strongly associated with reduced mor-
tality during TB treatment (Table 4). The adjusted OR 
(aOR) for death in patients who received ART before or 
during TB treatment was 0.2 (95% CI 0.1–0.5) compared 
with that in patients who did not receive ART. Receiving 
co-trimoxazole was no longer signiﬁ  cantly associated with 
reduced mortality. We found virtually identical results 
when we did the following: 1) restricted our analysis to 
only those patients who received ART during TB treatment 
compared with patients who did not receive ART during 
TB treatment; 2) restricted our analysis to previously un-
treated, non-MDR patients without nontuberculous myco-
bacteria; 3) coded patients with unknown CD4 as having 
CD4 >200 cells/mm3, as having CD4 <50 cells/mm3, or as 
missing (i.e., removed from the analysis). All analyses also 
produced essentially identical results when we reclassiﬁ  ed 
cases of default as death.
When we restricted our analysis to sputum smear–
positive patients, we found a similarly strong beneﬁ  cial 
effect for ART. Because no deaths occurred in the group 
of smear-positive patients with CD4 >200 cells/mm3, we 
modeled CD4 as a continuous variable. The aOR was 0.1 
(95% CI 0.0–0.9). Results were similar when we recoded 
patients with unknown CD4 count as having CD4 equal to 
50 cells/mm3 (indicative of profound immunosuppression 
and imminent risk of death) or 250 cells/mm3 (not eligible 
for antiretroviral treatment in many country guidelines be-
cause they are relatively immune competent). Because of 
small sample size, we were only able to perform univari-
ate, not multivariate, analysis for the 57 culture-positive 
patients who had an outcome of cured, completed, failed, 
or died. One (8%) of 13 culture-positive patients receiving 
ART died compared with 17 (36%) of 47 culture-positive 
patients not receiving ART (RR 0.2, 95% CI 0.0–1.5; abso-
lute risk reduction 28; number-needed-to-treat 3.6).
Because patients who died soon after TB diagnosis 
were also unlikely to have begun ART, we modeled the 
effect of ART after excluding 32 patients who died in the 
ﬁ  rst month of beginning TB treatment (aOR 0.1, 95% CI 
0.0–0.8) and the additional 16 patients who died in the sec-
ond month (aOR 0.1, 95% CI 0.0–1.2). Results were simi-
lar when we recoded patients with unknown CD4 count as 
having CD4 equal to 50 cells/mm3 or 250 cells/mm3, except 
that the effect of ART was now statistically signiﬁ  cant for 
the analysis excluding deaths within the ﬁ  rst and second 
months (aOR 0.1, 95% CI 0.0–0.7 for unknown CD4 re-
coded as 50 cells/mm3; aOR 0.1; 95% CI 0.0–0.9 for un-
known CD4 recoded as 250 cells/mm3).
We explored the effect of co-trimoxazole on mortality 
for the 218 patients who did not receive ART: 52 (38%) of 
137 patients receiving co-trimoxazole died compared with 
42 (51%) of 82 patients not receiving co-trimoxazole (RR 
0.7, CI 0.6–1.0; absolute risk reduction 13; number-needed-
to-treat 7.7). The association between co-trimoxazole and 
survival was not statistically signiﬁ  cant when we excluded 
patients who died in the ﬁ  rst month (RR 0.9, CI 0.5–1.5) 
or in the ﬁ  rst 2 months (RR 1.2, CI 0.5–3.0) and when we 
limited the analysis to smear-positive patients (RR 0.8, CI 
0.5–1.3). In multivariate analysis of patients who did not 
receive ART and adjusting for CD4 count, smear status, 
and hospital providing treatment, co-trimoxazole was not 
associated with survival (aOR 0.9, CI 0.5–1.9).
Table 2. Results of culture and susceptibility testing performed on HIV-infected patients with pulmonary TB, stratified by sputum
smear–positive versus –negative results, Ubon-ratchathani, February 2003 through January 2004* 
Characteristic Smear-positive (n = 120), no. (%)  Smear-negative (n = 107), no. (%) 
Sputum culture performed  93/120 (78)  52/107 (49) 
Culture positive for nontuberculous mycobacteria  2/93 (2)  0/52 (0) 
Contaminated 5/93 (5)  6/52 (12) 
Culture negative  21/93 (23)  43/52 (83) 
Culture positive for Mycobacterium tuberculosis 65/93 (70)  3/52 (6) 
Multidrug-resistant TB  4/65 (6)  0/3 (0) 
Previously treated  1/4 (25)  NA
*TB, tuberculosis; NA, not available. Antiretroviral Therapy and Tuberculosis
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Discussion
In this prospective, population-based study from a ru-
ral province in northeastern Thailand, we documented a 
high rate of death in HIV-infected TB patients and a sub-
stantial reduction in the risk for death during TB treatment 
for patients receiving ART. In this population, TB occurred 
predominantly in persons with preexisting HIV diagnoses 
and low CD4 counts, and, as expected, the CD4 count was 
inversely related to death. These ﬁ  ndings are more consis-
tent with the epidemiology of TB in high-income countries, 
such as the United States, than that in sub-Saharan Africa, 
where studies have found that most TB and HIV have not 
previously been diagnosed in patients with HIV infection 
and that TB occurs across a broad spectrum of immune 
suppression (21–26). Although CD4 counts were not re-
corded for many patients in this study, we can infer from 
the high mortality in these patients that their CD4 counts 
were probably low. Research would be needed to document 
whether data from this evaluation are representative of oth-
er settings in Thailand or Southeast Asia. That TB occurred 
predominantly in persons with advanced, diagnosed HIV 
infection suggests that interventions targeted speciﬁ  cally at 
HIV-infected patients—such as early ART, treatment of la-
tent TB infection, and earlier screening for and treatment of 
TB disease in household contacts of TB patients and during 
routine HIV care—are also needed to reduce incidence and 
mortality of HIV-associated TB.
Given the advanced immune suppression in this popu-
lation, that ART improved survival during TB treatment 
is not surprising. The magnitude of beneﬁ  t, however, was 
substantial. Treating 3 HIV-infected TB patients with ART 
in this population would translate into 1 life saved during 
TB treatment. In fact, co-trimoxazole, which is known 
to save lives during TB treatment in Africa (27), was not 
signiﬁ  cantly associated with survival after adjusting for 
ART use. Co-trimoxazole protects AIDS patients against 
a wide range of infections that commonly occur in Thai-
land, including Pneumocystis jirovecii and Toxoplasma sp. 
(28). We were not able to demonstrate a survival beneﬁ  t 
of co-trimoxazole in patients receiving ART or those not 
receiving ART. We do not know whether this is a true phe-
nomenon or attributable to bias, misclassiﬁ  cation, or small 
Table 3. Univariate analysis of risk factors for death among HIV-infected TB patients with outcomes of cured, completed, failed, or 
died, stratified by all patients versus pulmonary, smear-positive patients, Ubon-ratchathani, February 2003 through January 2004*
All TB patients (N = 286)  Smear-positive TB patients (n = 104) 
Characteristic Died, no./total (%)  RR (95% CI)  Died, no./total (%)  RR (95% CI) 
Sex 
   Male  69/193 (36)  1.2 (0.8–1.6)  33/72 (46)  2.3 (1.1–4.7) 
   Female  30/97 (31)  Ref 7/35 (20)  Ref
Age
   <18 y  4/19 (21)  0.6 (0.2–1.4)  0/1 (0)  0 (0–0) 
   18–34 y  60/168 (36)  Ref 26/60 (43)  Ref
>35 y  35/103 (34)  1.0 (0.7–1.3)  14/46 (30)  0.7 (0.4–1.2) 
Type, location of TB 
  Sputum smear-positive, pulmonary  40/107 (37)  Ref NA NA
  Sputum smear-negative, pulmonary  38/96 (40)  1.1 (0.8–1.5)  NA NA
   Extrapulmonary  21/87 (24)  0.7 (0.4–1.0)  NA NA
CD4 count (cells/mm
3)
>200 1/22 (5)  Ref 0/8 (0)  Ref
   100–199  5/33 (15)  3.3 (0.4–26.6)  2/12 (17)  Undefined
   50–99  9/35 (26)  5.7 (0.8–41.6)  1/10 (10)  Undefined
   <50  22/92 (24)  5.3 (0.8–37.0)  9/34 (27)  Undefined
   Unknown  62/108 (57)  12.6 (1.9–86.3)  28/43 (65)  Undefined
Co-trimoxazole during TB treatment 
   Received  57/208 (27)  0.5 (0.4–0.7)  21/71 (30)  0.6 (0.4–0.9) 
   Did not receive  42/82 (51)  Ref 19/36 (53)  Ref
Antiretroviral therapy before or during TB treatment 
   Received  5/71 (7)  0.2 (0.1–0.4)  1/23 (4)  0.1 (0.0–0.7) 
   Did not receive  94/219 (43)  Ref 39/84 (46)  Ref
Sputum culture† 
   Culture positive  18/60 (30)  Ref 18/59 (31)  Ref
   Not culture positive  81/230 (35)  1.2 (0.8–1.8)‡  22/48 (46)  1.5 (0.9–2.5)‡ 
   Culture negative  21/60 (35)  1.2 (0.7–2.0)‡  9/20 (45)  1.5 (0.8–2.7)‡ 
*TB, tuberculosis; RR, relative risk; CI, confidence interval; Ref, referent; NA, not applicable. 
†”Culture positive” includes all patients with a sputum culture positive for Mycobacterium tuberculosis (MTB). “Not culture positive” includes any patients 
without a culture positive for MTB, regardless of whether they had a specimen sent for culture or not. “Culture negative” includes only patients with a 
sputum culture negative for MTB. 
‡Compared with culture positive. RESEARCH
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sample size. Further studies are needed to evaluate the sur-
vival beneﬁ  t of co-trimoxazole in HIV-infected TB patients 
in Thailand. Our sample size was too small to compare out-
comes between patients receiving regimens with efavirenz 
versus nevirapine or to compare outcomes between patients 
who received ART during the ﬁ  rst 2 months of TB treat-
ment compared with those who received ART later.
Our evaluation reinforces the importance of provid-
ing TB patients with early access to HIV diagnosis and 
treatment, as recommended in WHO’s Interim Policy on 
TB/HIV Collaborative Activities (1). In this project, we 
found several missed opportunities, including HIV testing 
of TB patients, measurement of CD4 count, and initiation 
of co-trimoxazole and ART. Educating providers about the 
life-saving beneﬁ  ts of ART in HIV-infected TB patients is 
a major priority, but more data from observational stud-
ies and clinical trials are needed to provide evidence-based 
guidance about the optimum timing of ART and the inci-
dence and management of overlapping toxicities and im-
mune-reconstitution syndrome.
This study has several major limitations. First, we do 
not know the reasons why patients did not receive ART. 
Many patients who did not receive ART were likely deemed 
too ill and, therefore, unlikely to beneﬁ  t from ART. This 
bias would exaggerate the beneﬁ  t of ART; survival would 
determine ART use, not the reverse. To address this issue, 
we controlled for 2 factors likely to predict when a patient 
would receive ART, such as CD4 count and hospital of 
care (a surrogate for physician preference or resources). 
Moreover, after excluding persons who died within the ﬁ  rst 
2 months of TB treatment, i.e., persons likely to receive 
minimal beneﬁ  t from ART and likely to have been deemed 
too ill to receive ART, we still identiﬁ  ed a substantial ben-
eﬁ  t for ART.
Another limitation is that not all TB patients under-
went HIV testing, which could skew our population toward 
those patients most likely to have advanced immune sup-
pression and, therefore, most likely to beneﬁ  t from ART. 
Since these data were collected, rates of HIV testing of TB 
patients have increased substantially in Ubon-ratchathani, 
but the proportion identiﬁ  ed as HIV infected remains simi-
lar to what it was in this study, suggesting that the num-
ber of HIV infections missed in this study population was 
small. This study was also based on surveillance and moni-
toring data from a public health program, which, though 
prospectively collected, necessarily relied on incomplete 
data, such as from routine medical records. Core data ele-
ments, such as CD4 count, were missing for many patients, 
and data about adverse events and causes of death, which 
are critical to assessing the risks of combined ART and TB 
treatment, were not collected. Low rates of culture posi-
tivity, particularly in smear-negative patients, leave open 
the possibility that some patients did not, in fact, have TB. 
Since this study, we have identiﬁ  ed several reasons for the 
low yield of culture, including delayed transport times for 
specimens and inadequate specimen collection; efforts to 
improve these procedures have since been implemented. 
Even though many patients were not culture conﬁ  rmed 
in this study, sputum smear–positive patients beneﬁ  ted 
strongly from ART, which suggests that misdiagnosis of 
TB is an unlikely explanation for our ﬁ  ndings.
Major strides have been made in enhancing access to 
HIV treatment in the developing world. Nevertheless, as 
this study shows, deaths of patients with both TB and HIV 
remain high, and, even in a country such as Thailand with 
high rates of access to ART, few HIV-infected TB patients 
receive ART. Globally, measures to save lives of patients 
with both diseases have focused on making TB and HIV 
programs collaborate more closely. To that end, more data 
from these settings are urgently needed to convince poli-
cymakers in countries affected by this syndemic about the 
critical importance of rapidly expanding access to ART, 
particularly for HIV-infected TB patients.
Table 4. Multivariate analysis of risk factors for death among HIV-infected TB patients with outcomes of cured, completed, failed, or 
died and adjusted for site of treating facility,* Ubon-ratchathani, February 2003 through January 2004† 
Characteristic Adjusted OR (95% CI) 
Antiretroviral therapy before or during TB treatment  0.2 (0.1–0.5)




   100–199  5.5 (0.6–52.6) 
   50–99  9.3 (1.0–82.9)
   <50  9.7 (1.2–78.4) 
   Unknown  29.9 (3.8–238.0)
Type, location of TB 
   Sputum smear–positive, pulmonary  Referent
   Sputum smear–negative, pulmonary  1.3 (0.7–2.6) 
   Extrapulmonary  0.5 (0.2–1.0) 
*Data not shown. 
†TB, tuberculosis; OR, odds ratio; CI, confidence interval. Antiretroviral Therapy and Tuberculosis
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